Rebounders (n = 66) | Secondary controllers (n = 2) | ||
---|---|---|---|
P1 | P2 | ||
Sex: | |||
Male | 43 | M | F |
Female | 23 | ||
Age at start HAART (years) | 37 (20-61)a | 50 b | 45 |
Clinical parameters of infection | |||
Days since diagnosis | 4563 (1529-8469) | 7709 | 4191 |
Days on HAART | 1364 (160-4063) | 4257 | 2860 |
Days off HAART | 541 (182-2468) | not restarted | not restarted |
CD4 at start HAART | 292 (23-804) | 228 | 377 |
CD4 at stop HAART | 698 (113-1669) | 458 | 1326 |
VL before start HAART | 4.98 (3.47-6.0) | 3.4 (under AZT) | 4.6 (treatment naïve) |
VL 6 months after stopping HAART | 4.69 (3.04-6.0) | <1.6 | < 1.6 |
Months with undetectable VL under HAART | 25 (1-98) | 65 | 83 |
HIV-1 subtype | |||
3 A | B | D | |
17 B | |||
1 D | |||
2 H | |||
3 CRF_01 | |||
4 CRF_02 | |||
1 CRF_36 | |||
1 CRF_D/F1 | |||
34 unknown | |||
Markers of immune activation | |||
sCD14 (ng/ml) | |||
T1 | 2066 (1682-2380)c | ND | 1648 |
T2 | 2032 (1627-2499) | 3037 | 3119 |
T3 | 2173 (1744-2740) | 4269 | 1760 |
LPS (EU/ml) | |||
T1 | 4.04 (3.02-6.45) | ND | 7.4 |
T2 | 4.17 (3.02-5.8) | 3.41 | 3.36 |
T3 | 4.61 (3.41-5.35) | 4.31 | 4.43 |
Neopterin (nmol/l) | |||
T1 | 8.15 (4.93-11.61) | ND | 13.14 |
T2 | 18.22 (11.36-25.07) | 9.35 | 17.76 |
T3 | 8.75 (5.37-17.1) | 5.16 | 15.03 |
Beta-2 microglobulin (μg/ml) | |||
T1 | 448 (346-596) | ND | 300 |
T2 | 252 (226-308) | 336 | 212 |
T3 | 466 (344-566) | 694 | 280 |
HLA types | B4101, B5201 | B1402, B3501 |